Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/69263
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | White, Michael T. | - |
dc.contributor.author | Verity, Robert | - |
dc.contributor.author | Griffin, Jamie T. | - |
dc.contributor.author | Asante, Kwaku Poku | - |
dc.contributor.author | Owusu-Agyei, Seth | - |
dc.contributor.author | Greenwood, Brian | - |
dc.contributor.author | Drakeley, Chris | - |
dc.contributor.author | Gesase, Samwel | - |
dc.contributor.author | Lusingu, John | - |
dc.contributor.author | Ansong, Daniel | - |
dc.contributor.author | Adjei, Samuel | - |
dc.contributor.author | Agbenyega, Tsiri | - |
dc.contributor.author | Ogutu, Bernhards | - |
dc.contributor.author | Otieno, Lucas | - |
dc.contributor.author | Otieno, Walter | - |
dc.contributor.author | Agnandji, Selidji Todagbe | - |
dc.contributor.author | Lell, Bertrand | - |
dc.contributor.author | Kremsner, Peter G. | - |
dc.contributor.author | Hoffman, Irving | - |
dc.contributor.author | Martinson, Francis | - |
dc.contributor.author | Kamthunzi, Portia | - |
dc.contributor.author | Tinto, Halidou | - |
dc.contributor.author | Valéa, Innocent | - |
dc.contributor.author | Sorgho, Hermann | - |
dc.contributor.author | Oneko, Martina | - |
dc.contributor.author | Otieno, Kephas | - |
dc.contributor.author | Hamel, Mary J. | - |
dc.contributor.author | Salim, Nahya | - |
dc.contributor.author | Mtoro, Ali Takadir | - |
dc.contributor.author | Abdulla, Salim | - |
dc.contributor.author | Aide, Pedro Carlos Paulino | - |
dc.contributor.author | Sacarlal, Jahit | - |
dc.contributor.author | Aponte, John J. | - |
dc.contributor.author | Njuguna, Patricia | - |
dc.contributor.author | Marsh, Kevin | - |
dc.contributor.author | Bejon, Philip | - |
dc.contributor.author | Riley, Eleanor M. | - |
dc.contributor.author | Ghani, Azra C. | - |
dc.date.accessioned | 2016-02-04T13:45:39Z | - |
dc.date.available | 2016-02-04T13:45:39Z | - |
dc.date.issued | 2015-09-02 | - |
dc.identifier.issn | 1473-3099 | - |
dc.identifier.uri | http://hdl.handle.net/2445/69263 | - |
dc.description.abstract | BACKGROUND: The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done between 2009 and 2014. METHODS: Using data from 8922 African children aged 5-17 months and 6537 African infants aged 6-12 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time. FINDINGS: RTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5-17 months than in those aged 6-12 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6-12 weeks and higher immunogenicity in those aged 5-17 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane according to a biphasic exponential distribution. In participants aged 5-17 months, the half-life of the short-lived component of the antibody response was 45 days (95% credible interval 42-48) and that of the long-lived component was 591 days (557-632). After primary vaccination 12% (11-13) of the response was estimated to be long-lived, rising to 30% (28-32%) after a booster dose. An anti-circumsporozoite antibody titre of 121 EU/mL (98-153) was estimated to prevent 50% of infections. Waning anti-circumsporozoite antibody titres predict the duration of efficacy against clinical malaria across different age categories and transmission intensities, and efficacy wanes more rapidly at higher transmission intensity. INTERPRETATION: Anti-circumsporozoite antibody titres are a surrogate of protection for the magnitude and duration of RTS,S/AS01 efficacy, with or without a booster dose, providing a valuable surrogate of effectiveness for new RTS,S formulations in the age groups considered. FUNDING: UK Medical Research Council. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Ltd. | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1016/S1473-3099(15)00239-X | - |
dc.relation.ispartof | The Lancet. Infectious Diseases, 2015, vol. 15, num. 12, p. 1450-1458 | - |
dc.relation.uri | http://dx.doi.org/10.1016/S1473-3099(15)00239-X | - |
dc.rights | cc by (c) White et al., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Vacuna de la malària | - |
dc.subject.classification | Malària | - |
dc.subject.classification | Plasmodium falciparum | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.other | Malaria vaccine | - |
dc.subject.other | Malaria | - |
dc.subject.other | Plasmodium falciparum | - |
dc.subject.other | Clinical trials | - |
dc.title | Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2016-02-02T15:35:22Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 26342424 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
white2015_1979.pdf | 578.43 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License